Taro Provides Results for Quarter Ended June 2018

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the
“Company”) today provided unaudited financial results for the quarter
ended June 30, 2018.

Quarter ended June 30, 2018 Highlights – compared to June 30, 2017

  • Net sales of $154.6 million, decreased $6.7 million, or 4.2%, the
    result of continuing increased competition and the challenging pricing
    environment; despite an overall increase in volumes of 11.1%.
  • Gross profit of $100.1 million, decreased $16.5 million and as a
    percentage of net sales, was 64.7% compared to 72.2%.
  • Research and development expenses of $13.3 million decreased $1.3
  • Selling, marketing, general and administrative expenses of $23.6
    million decreased $0.7 million.
  • Operating income of $63.2 million decreased $14.5 million and as a
    percentage of net sales was 40.8% as compared to 48.1%.
  • Interest and other financial income increased $3.3 million to $7.8
  • Foreign Exchange (FX) income of $10.0 million compared to FX expense
    of $19.6 million ─ a favorable impact of $29.6 million, principally
    the result of the weakening of the Canadian dollar vs. the U.S. dollar.
  • Tax expense of $14.1 million increased $4.1 million with the effective
    tax rate increasing to 17.3% from 15.5%.
  • Net income attributable to Taro was $67.3 million compared to $54.5
    million, resulting in diluted earnings per share of $1.71 compared to

Cash Flow and Balance Sheet Highlights

  • Cash flow provided by operations was $82.4 million compared to $72.7
    million for the three months ended June 30, 2017.
  • As of June 30, 2018, cash, including short-term and long-term bank
    deposits and marketable securities, increased $63.6 million to $1.7
    billion from March 31, 2018. Cash reflects the $24.7 million impact
    from the Company’s share repurchases during the current quarter.

Mr. Uday Baldota, Taro’s CEO stated, “We continue to face an overall
market trend, particularly in the U.S., that is not dramatically
changing, and depending on the product(s), price deflation continues to
be a challenge. We continue to maintain a development pipeline investing
only in those products which are viable. From a business development
perspective, we will continue to evaluate opportunities that make
strategic sense and remain disciplined in our approach.”

FDA Approvals and Filings

The Company recently received two approvals from the U.S. Food and Drug
Administration (“FDA”) for Abbreviated New Drug Applications (“ANDAs”);
Benzoyl Peroxide; Clindamycin Phosphate Topical Gel 5%; 1% and
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/3.75%. The Company
currently has a total of thirty-two ANDAs awaiting FDA approval,
including five tentative approvals.

Share Repurchase Program – Returning Capital to

On November 23, 2016, the Company announced that its Board of Directors
approved a $250 million share repurchase of ordinary shares. Under this
authorization, repurchases may be made from time to time at the
Company’s discretion, based on ongoing assessments of the capital needs
of the business, the market price of its stock, and general market
conditions. The repurchase authorization enables the Company to purchase
its ordinary shares through open market purchases, negotiated
transactions or other means, including 10b5-1 trading plans in
accordance with applicable securities laws or other restrictions. On
November 7, 2017, the Board extended the share repurchase program for
one year.

During the quarter, the Company repurchased 202,325 shares at an average
price of $100.34. Through June 30, 2018, in total under the
authorization, the Company has repurchased 1,806,984 shares at an
average price of $102.86; with $64.1 million remaining.

Form 20-F Filings with the SEC

On June 21, 2018, the Company filed its Annual Report on Form 20-F with
the U.S. Securities and Exchange Commission (“SEC”) for the fiscal year
ended March 31, 2018.

The Company cautions that the foregoing financial information is
presented on an unaudited basis and is subject to change.


About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the
highest quality healthcare products. For further information on Taro
Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.


The unaudited consolidated financial statements have been prepared on
the same basis as the annual consolidated financial statements and, in
the opinion of management, reflect all adjustments necessary to present
fairly the financial condition and results of operations of the Company.

The unaudited consolidated financial statements should be read in
conjunction with the Company’s audited consolidated financial statements
included in the Company’s Annual Report on Form 20-F, as filed with the

Certain statements in this release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
These statements include, but are not limited to,
statements that do not describe historical facts or that refer or relate
to events or circumstances the Company “estimates,” “believes,” or
“expects” to happen or similar language, and statements with respect to
the Company’s financial performance, availability of financial
information, and estimates of financial results and information for
fiscal year 2019.
Although the Company believes the expectations
reflected in such forward-looking statements to be based on reasonable
assumptions, it can give no assurances that its expectations will be
Factors that could cause actual results to differ
include general domestic and international economic conditions, industry
and market conditions, changes in the Company’s financial position,
litigation brought by any party in any court in Israel, the United
States, or any country in which Taro operates, regulatory and
legislative actions in the countries in which Taro operates, and other
risks detailed from time to time in the Company’s SEC reports, including
its Annual Reports on Form 20-F.
Forward-looking statements are
applicable only as of the date on which they are made.
Company undertakes no obligations to update, change or revise any
forward-looking statement, whether as a result of new information,
additional or subsequent developments or otherwise.

**Financial Tables Follow**

(U.S. dollars in thousands, except share data)
Three Months Ended June 30,
2018 2017
Sales, net $ 154,618 $ 161,321
Cost of sales   54,536     44,778  
Gross profit 100,082 116,543
Operating Expenses:
Research and development 13,345 14,658
Selling, marketing, general and administrative   23,582     24,249  
Operating income 63,155 77,636
Financial (income) expense, net:
Interest and other financial income (7,804 ) (4,476 )
Foreign exchange (income) expense (9,962 ) 19,642
Other gain, net   603     2,119  
Income before income taxes 81,524 64,589
Tax expense   14,096     9,987  
Income from continuing operations 67,428 54,602
Net loss from discontinued operations attributable to Taro       (47 )
Net income 67,428 54,555
Net income attributable to non-controlling interest   151     58  
Net income attributable to Taro $ 67,277   $ 54,497  
Net income per ordinary share from continuing operations
attributable to Taro:
Basic and Diluted $ 1.71   $ 1.35  
Net loss per ordinary share from discontinued operations
attributable to Taro:
Basic and Diluted $   $ (0.00 ) *
Net income per ordinary share attributable to Taro:
Basic and Diluted $ 1.71   $ 1.35  
Weighted-average number of shares used to compute net income per
Basic and Diluted   39,260,218     40,489,470  
* Amount is less than $0.01
May not foot due to rounding.
(U.S. dollars in thousands)
June 30, March 31,
2018 2018
ASSETS (unaudited) (audited)
Cash and cash equivalents $ 641,989 $ 576,611
Short-term and current maturities of long-term bank deposits 174,158 296,188
Marketable securities 597,533 549,821
Accounts receivable and other:
Trade, net 209,135 206,455
Corporate tax receivable 44,166 100,380
Other receivables and prepaid expenses 25,184 22,585
Inventories   141,034   144,595
TOTAL CURRENT ASSETS 1,833,199 1,896,635
Long-term deposits and marketable securities 298,145 225,639
Property, plant and equipment, net 194,797 193,727
Deferred income taxes 122,408 87,257
Other assets   29,340   29,952
TOTAL ASSETS $ 2,477,889 $ 2,433,210
Trade payables $ 26,513 $ 25,697
Other current liabilities   166,116   190,059
Deferred taxes and other long-term liabilities   5,196   7,055
TOTAL LIABILITIES 197,825 222,811
Taro shareholders’ equity 2,274,672 2,205,158
Non-controlling interest   5,392   5,241
(U.S. dollars in thousands)
Three Months Ended June 30,
2018 2017
Cash flows from operating activities:
Net income $ 67,428 $ 54,555
Adjustments required to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 4,299 3,775
Realized gain on sale of marketable securities and long-lived assets (7 ) (247 )
Change in derivative instruments, net 3,546 (3,093 )
Effect of change in exchange rate on inter-company balances,
marketable securities and bank deposits
(28,918 ) 22,078
Deferred income taxes, net 1,575 4,825
(Increase) decrease in trade receivables, net (2,897 ) 18,270
Decrease (increase) in inventories, net 2,653 (2,114 )
Decrease (increase) in other receivables, income tax receivable,
prepaid expenses and other
52,479 (21,483 )
Decrease in trade, income tax, accrued expenses, and other payables (17,408 ) (3,377 )
Income from marketable securities, net   (310 )   (521 )
Net cash provided by operating activities   82,440     72,668  
Cash flows from investing activities:
Purchase of plant, property & equipment (6,078 ) (4,557 )
Investment in other intangible assets (45 ) (2,056 )
Proceeds from short-term bank deposits, net 51,345 46,940
Proceeds from long-term deposits and other assets 70,685
Investment in marketable securities, net   (107,644 )   (275,128 )
Net cash used in investing activities   8,263     (234,801 )
Cash flows from financing activities:
Purchase of treasury stock   (24,655 )   (8,489 )
Net cash used in financing activities   (24,655 )   (8,489 )
Effect of exchange rate changes on cash and cash equivalents   (670 )   936  
Increase (decrease) in cash and cash equivalents 65,378 (169,686 )
Cash and cash equivalents at beginning of period   576,611     600,399  
Cash and cash equivalents at end of period $ 641,989   $ 430,713  
Cash Paid during the year for:
Income taxes $ 36,830   $ 29,595  
Cash Received during the year for:
Income taxes $ 60,544   $  
Non-cash investing transactions:
Purchase of property, plant and equipment included in accounts
$ 1,823   $ 1,180  
Non-cash financing transactions:
Purchase of marketable securities $ 8,629   $  


Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer, (914)
J. Coote, (914) 345-9001
AVP, Business Finance, Treasurer and
Investor Relations